Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma
Authors
Keywords
-
Journal
Gastric Cancer
Volume 24, Issue 3, Pages 721-730
Publisher
Springer Science and Business Media LLC
Online
2021-03-23
DOI
10.1007/s10120-020-01153-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX vs EOX alone for first-line treatment of advanced CLDN18.2 positive gastric and gastro-oesophageal adenocarcinoma
- (2021) U. Sahin et al. ANNALS OF ONCOLOGY
- A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study
- (2019) O Türeci et al. ANNALS OF ONCOLOGY
- A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer
- (2018) Ugur Sahin et al. EUROPEAN JOURNAL OF CANCER
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
- (2018) K Muro et al. ANNALS OF ONCOLOGY
- Characterization of zolbetuximab in pancreatic cancer models
- (2018) Ӧzlem Türeci et al. OncoImmunology
- Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry
- (2017) A. Carmona-Bayonas et al. Gastric Cancer
- It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma
- (2017) Elena Elimova et al. JOURNAL OF CLINICAL ONCOLOGY
- Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases
- (2017) Srinivas Raman et al. QUALITY OF LIFE RESEARCH
- Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) E. C. Smyth et al. ANNALS OF ONCOLOGY
- Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: A systematic review
- (2016) Silvia Sommariva et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Quality of Life in the Trastuzumab for Gastric Cancer Trial
- (2014) Taroh Satoh et al. ONCOLOGIST
- Clinical epidemiology of gastric cancer
- (2014) TL Ang et al. SINGAPORE MEDICAL JOURNAL
- Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients
- (2011) J. Maringwa et al. ANNALS OF ONCOLOGY
- Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development
- (2008) U. Sahin et al. CLINICAL CANCER RESEARCH
- Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
- (2008) David Cunningham et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started